|
đ N-nitroso Ticagrelor
|
|
21
|
3857
|
July 17, 2026
|
|
Trace-level LCâMS/MS quantification of two nitrosamine impurities formed from terazosin-related impurities in pharmaceutical products and greenness assessment-Pub
|
|
2
|
158
|
July 15, 2026
|
|
In Vitro Metabolism Study of NDSRIs
|
|
4
|
394
|
July 9, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
4
|
354
|
July 8, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
10
|
800
|
July 7, 2026
|
|
Analytical Challenges in Quantifier Ion Selection Due to Mass Error Variability
|
|
7
|
289
|
July 2, 2026
|
|
NDSRI growth with respect to age
|
|
12
|
552
|
June 25, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
251
|
June 19, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
22
|
5527
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
147
|
June 16, 2026
|
|
Finasteride NDSRI
|
|
2
|
167
|
June 15, 2026
|
|
Complex versus simple N-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigms -Pub
|
|
7
|
592
|
June 3, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
393
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
281
|
June 1, 2026
|
|
Solution stability of NDSRI
|
|
8
|
387
|
May 25, 2026
|
|
Nitrite in Amines
|
|
15
|
969
|
May 21, 2026
|
|
Development and Validation of a Trace-Level LCâMS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
103
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2907
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
94
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LCâHRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
125
|
May 20, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1153
|
May 18, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
397
|
May 13, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
183
|
May 8, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of NâNitrosamines-Pub
|
|
2
|
174
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
507
|
April 30, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
135
|
April 29, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
476
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
217
|
April 20, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
223
|
April 17, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes â N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
131
|
April 14, 2026
|